Ligand Pharmaceuticals (LGND) EPS (Basic) (2016 - 2025)
Historic EPS (Basic) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $5.99.
- Ligand Pharmaceuticals' EPS (Basic) rose 163589.74% to $5.99 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.31, marking a year-over-year decrease of 1216.73%. This contributed to the annual value of -$0.22 for FY2024, which is 10708.84% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported EPS (Basic) of $5.99 as of Q3 2025, which was up 163589.74% from $0.25 recorded in Q2 2025.
- Ligand Pharmaceuticals' 5-year EPS (Basic) high stood at $5.99 for Q3 2025, and its period low was -$2.88 during Q2 2024.
- Over the past 5 years, Ligand Pharmaceuticals' median EPS (Basic) value was $0.25 (recorded in 2025), while the average stood at $0.63.
- As far as peak fluctuations go, Ligand Pharmaceuticals' EPS (Basic) crashed by 231538.46% in 2024, and later soared by 163589.74% in 2025.
- Over the past 5 years, Ligand Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.13 in 2021, then tumbled by 30.88% to -$0.17 in 2022, then skyrocketed by 694.47% to $1.04 in 2023, then crashed by 263.44% to -$1.7 in 2024, then soared by 452.41% to $5.99 in 2025.
- Its last three reported values are $5.99 in Q3 2025, $0.25 for Q2 2025, and -$2.21 during Q1 2025.